J&J to buy cancer drug technology developer Firefly Bio for $1 billion

AI assessment

This acquisition by Johnson & Johnson (JNJ) of a cancer drug tech company could enhance J&J's product pipeline and innovation capabilities, potentially boosting future revenue streams.

Model: qwen2.5:3b · 2026-06-08 14:43